Table 2.
The proportion (%) of bloodstream infection (BSI) episodes with microbe(s) non-susceptible to some common antibiotic regimens
| Total | 2002–2005a | 2006–2009 | 2010–2013 | p for trend | |
|---|---|---|---|---|---|
| Penicillin-gentamicin | |||||
| Total | 6.1 | 4.4 | 6.1 | 7.5 | 0.011 |
| Community acquired | 4.3 | 2.2 | 5.7 | 5.0 | 0.22 |
| Health care-associated | 6.7 | 7.4 | 5.8 | 7.2 | 0.16 |
| Hospital acquired | 10.2 | 4.4 | 8.6 | 16.5 | 0.023 |
| p for trend | 0.006 | 0.058 | 0.46 | 0.003 | |
| Penicillin-gentamicin-metronidazole | |||||
| Total | 3.5 | 1.9 | 3.0 | 5.2 | <0.001 |
| Community acquired | 1.4 | 0.3 | 1.8 | 2.1 | 0.28 |
| Health care-associated | 4.8 | 4.6 | 3.2 | 6.3 | 0.045 |
| Hospital acquired | 6.9 | 2.2 | 6.2 | 11.7 | 0.026 |
| p for trend | <0.001 | 0.007 | 0.15 | 0.001 | |
| Piperacillin/tazobactam | |||||
| Total (n = 1413) | 7.6 | 7.4 | 7.7 | 0.25 | |
| Community acquired (n = 617) | 3.6 | 2.9 | 4.2 | 0.27 | |
| Health care-associated (n = 612) | 8.8 | 9.4 | 8.4 | 0.31 | |
| Hospital acquired (n = 184) | 8.8 | 9.4 | 17.0 | 0.31 | |
| p for trend | <0.001 | <0.001 | <0.001 | ||
| Piperacillin/tazobactam-gentamicin | |||||
| Total (n = 1413) | 3.0 | 2.4 | 3.6 | 0.21 | |
| Community acquired (n = 617) | 1.0 | 0.7 | 1.2 | 0.69 | |
| Health care-associated (n = 612) | 3.3 | 3.2 | 3.3 | 0.98 | |
| Hospital acquired (n = 184) | 9.2 | 4.9 | 12.6 | 0.12 | |
| p for trend | <0.001 | 0.037 | <0.001 | ||
| Piperacillin/tazobactam-gentamicin-metronidazole | |||||
| Total (n = 1413) | 2.6 | 1.7 | 3.4 | 0.065 | |
| Community acquired (n = 617) | 0.5 | 0.0 | 0.9 | 0.26 | |
| Health care-associated (n = 612) | 2.9 | 2.5 | 3.3 | 0.64 | |
| Hospital acquired (n = 184) | 8.7 | 4.9 | 11.7 | 0.12 | |
| p for trend | <0.001 | 0.004 | <0.001 | ||
| Imipenem | |||||
| Community acquired | 1.1 | 1.6 | 0.7 | 0.9 | 0.59 |
| Health care-associated | 6.5 | 9.1 | 5.8 | 5.7 | 0.39 |
| Hospital acquired | 10.6 | 11.1 | 7.4 | 12.6 | 0.14 |
| p for trend | <0.001 | <0.001 | 0.001 | <0.001 | |
| Cefotaxime | |||||
| Total | 17.8 | 17.5 | 18.7 | 17.3 | 0.68 |
| Community acquired | 10.8 | 11.0 | 11.4 | 10.1 | 0.69 |
| Health care-associated | 21.3 | 25.1 | 22.7 | 18.2 | 0.18 |
| Hospital acquired | 31.4 | 25.6 | 29.6 | 37.9 | 0.31 |
| p for trend | <0.001 | <0.001 | <0.001 | <0.001 | |
| Ceftazidime | |||||
| Total | 27.8 | 29.0 | 24.8 | 29.4 | 0.25 |
| Community acquired | 18.5 | 20.2 | 15.4 | 19.6 | 0.42 |
| Health care-associated | 31.3 | 36.0 | 28.2 | 31.3 | 0.37 |
| Hospital acquired | 49.6 | 46.7 | 45.7 | 55.3 | 0.46 |
| p for trend | <0.001 | <0.001 | <0.001 | <0.001 | |
aPiperacillin/tazobactam was not adopted in the first time period
The BSIs are stratified by place of acquisition and by time period (the total number in each cell is shown under the heading Place of acquisition in Table 1)